Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a ...
Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal ...
MedPage Today on MSN
Targeted duo wins again in BRAF-mutant colorectal cancer
SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated ...
Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022 ...
In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients ...
The FDA approved encorafenib (Braftovi) plus binimetinib (Mektovi) for BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC) as determined by an FDA-approved test, the agency announced on ...
First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic ...
NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...
In patients with skin or lung cancer, drugs that inhibit BRAF (v-raf murine sarcoma viral oncogene homolog B) mutations increase the risk for uveitis dramatically compared with conventional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback